Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of subcutaneous bapineuzumab in Alzheimer's disease
NCT00916617Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jun 2009
- Primary completion
- Sep 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bapineuzumab in Alzheimer's disease (AD), sponsored by Pfizer. Started Jun 2009; status: terminated.
02
Drugs
bapineuzumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00916617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00916617.